Loading...
•
Jun 30, 2022
Allakos Q2 2022 Earnings Report
Allakos reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
Allakos reported a net loss of $49.1 million in the second quarter of 2022, compared to a net loss of $57.2 million in the second quarter of 2021. The company's research and development expenses were $34.4 million, and general and administrative expenses were $14.7 million.
Submitted End-of-Phase 2 briefing package to FDA to discuss Phase 2 KRYPTOS data and development pathway of lirentelimab in patients with eosinophilic esophagitis (EoE).
Meeting with FDA scheduled for third quarter of 2022.
Report topline data from Phase 3 EoDyssey study of lirentelimab (AK002) in patients with eosinophilic duodenitis (EoD) in third quarter of 2022.
Initiate Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in third quarter of 2022.
Allakos
Allakos
Forward Guidance
This press release contains forward-looking statements regarding Allakos’ business plans and product candidates’ progress, the expected timing of FDA discussions and anticipated study results and the reporting of such results, plans relating to Allakos’ future IND-enabling studies and clinical trials, and Allakos’ upcoming milestones.